Patents-Review.com
ClassID:

97206 ⎘

C07K16/3053 - CPC Classification

Classification description:

Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells Skin, nerves, brain

Recent Application in this class:
#1
20260139061
2026-05-21

TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR

 #2
20260132183
2026-05-14

T CELL RECEPTORS DIRECTED AGAINST MELANOMA-ASSOCIATED ANTIGEN AND USES THEREOF

 #3
20260125470
2026-05-07

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #4
20260116992
2026-04-30

Targeting Intracellular Target-Binding Determinants with Intracellular Antibodies

 #5
20260116979
2026-04-30

COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER

 #6
20260116973
2026-04-30

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #7
20260070940
2026-03-12

STABILIZED IMMUNOGLOBULIN DOMAINS

 #8
20260053920
2026-02-26

NOVEL TCRs

 #9
20260049145
2026-02-19

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

 #10
20260022172
2026-01-22

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #11
20260008822
2026-01-08

BISPECIFIC FUSION PROTEIN USING ORTHOPOXVIRUS MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS I-LIKE PROTEIN (OMCP) AND TUMOR-SPECIFIC BINDING PARTNER

 #12
20250340657
2025-11-06

Methods of Treating IL1RAP Associated Cancers with Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) Antibodies

 #13
20250333502
2025-10-30

Methods for Manipulating Phagocytosis Mediated by CD47

 #14
20250313648
2025-10-09

Binders of Chondroitin Sulfate Proteoglycan (CSPG4) Polypeptides

 #15
20250257146
2025-08-14

ANTI-TROP2 ANTIBODY-DRUG CONJUGATE

 #16
20250249039
2025-08-07

PRAME IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING PRAME IMMUNOGENIC PEPTIDES, AND USES THEREOF

 #17
20250223335
2025-07-10

PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPY AGAINST HEAD AND NECK SQUAMOUS CELL CARCINOMA AND OTHER CANCERS

 #18
20250222030
2025-07-10

NK cells for Cell Therapy

 #19
20250179211
2025-06-05

Antibodies and antibody fragments and analogues specific for chondroitin sulfate

 #20
20250163178
2025-05-22

METHODS AND COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR TARGETING CANCER CELLS

 #21
20250163177
2025-05-22

BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS

 #22
20250163174
2025-05-22

CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER

 #23
20250163159
2025-05-22

ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES

 #24
20250154274
2025-05-15

USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT

 #25
20250114392
2025-04-10

BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICRENVIRONMENT

 #26
20250114391
2025-04-10

BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT

 #27
20250092133
2025-03-20

BISPECIFIC ANTIBODY CONSTRUCTS FOR CDH3 AND CD3

 #28
20250084160
2025-03-13

ANTIBODIES TARGETING CDH19 FOR MELANOMA

 #29
20250043028
2025-02-06

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #30
20240425616
2024-12-26

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #31
20240425558
2024-12-26

PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS

 #32
20240360235
2024-10-31

USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT

 #33
20240350528
2024-10-24

BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT

 #34
20240343808
2024-10-17

ANTIBODY MOLECULES TO PG-L1 AND METHODS OF TREATING CANCER AND INFECTIOUS DISEASES

 #35
20240247059
2024-07-25

HUMANIZED ANTIBODIES TO LIV-1 AND USE OF SAME TO TREAT CANCER

 #36
20240239910
2024-07-18

BI-SPECIFIC ACTIVATORS FOR TUMOR THERAPY

 #37
20240238396
2024-07-18

TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRvIII CHIMERIC ANTIGEN RECEPTOR

 #38
20240166741
2024-05-23

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

 #39
20240141044
2024-05-02

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #40
20240122976
2024-04-18

IMMUNE CELLS EXPRESSING AN ANTIGEN BINDING RECEPTOR AND A CHIMERIC COSTIMULATORY RECEPTOR

 #41
20240100156
2024-03-28

METHODS AND COMPOSITIONS FOR ENHANCING THE POTENCY OF SUPERANTIGEN MEDIATED CANCER IMMUNOTHERAPY

 #42
20240091354
2024-03-21

COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTIBODY

 #43
20240084033
2024-03-14

CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO

 #44
20240083967
2024-03-14

T CELL RECEPTORS AND USES THEREOF

 #45
20240052057
2024-02-15

Targeting Intracellular Target-Binding Determinants with Intracellular Antibodies

 #46
20240052056
2024-02-15

Targeting Intracellular Target-Binding Determinants with Intracellular Antibodies

 #47
20240043556
2024-02-08

ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS

 #48
20240042022
2024-02-08

ANTIBODIES BINDING TO CD3

 #49
20240026026
2024-01-25

Targeting intracellular target-binding determinants with intracellular antibodies

 #50
20240018263
2024-01-18

ANTIBODIES TARGETING GLIOBLASTOMA STEM-LIKE CELLS AND METHODS OF USE THEREOF

 #51
20240010724
2024-01-11

Antibody Constructs for CDH19 and CD3

 #52
20230340160
2023-10-26

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #53
20230312731
2023-10-05

HUMANIZED ANTIBODY TARGETING THE TUMOR ASSOCIATED ANTIGEN IL13RA2

 #54
20230293687
2023-09-21

T CELLS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF

 #55
20230287118
2023-09-14

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #56
20230277662
2023-09-07

ANTIBODIES BINDING TO CD3

 #57
20230242666
2023-08-03

Methods and Compositions for the Reduction of Chimeric Antigen Receptor Tonic Signaling

 #58
20230227542
2023-07-20

METHODS OF TREATING SKIN CANCER BY ADMINISTERING A PD-1 INHIBITOR

 #59
20230227518
2023-07-20

Peptides for use in immunotherapy against cancers

 #60
20230227517
2023-07-20

NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS

 #61
20230192886
2023-06-22

ADOPTIVE CELL THERAPY COMBINATION TREATMENT AND COMPOSITIONS THEREOF

 #62
20230192884
2023-06-22

BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS

 #63
20230190797
2023-06-22

COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY

 #64
20230136997
2023-05-04

TARGETING ABCB5 IN GLIOBLASTOMA MULTIFORME

 #65
20230136252
2023-05-04

GLYPICAN-2-BINDING MOIETIES, CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF

 #66
20230132241
2023-04-27

ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING PRAME

 #67
20230076791
2023-03-09

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #68
20230051701
2023-02-16

ANTIBODIES AGAINST CD73 AND USES THEREOF

 #69
20230041876
2023-02-09

Bispecific antibody constructs for CDH3 and CD3

 #70
20230002450
2023-01-05

Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner

 #71
20220411496
2022-12-29

MODULATION OF STIMULATORY AND NON-STIMULATORY MYELOID CELLS

 #72
20220403027
2022-12-22

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #73
20220324979
2022-10-13

COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER

 #74
20220323502
2022-10-13

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #75
20220323501
2022-10-13

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #76
20220308059
2022-09-29

BIOMARKERS FOR DISEASE PROGRESSION IN SQUAMOUS CELL CARCINOMA

 #77
20220288221
2022-09-15

ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES

 #78
20220267439
2022-08-25

Methods for Manipulating Phagocytosis Mediated by CD47

 #79
20220267395
2022-08-25

Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof

 #80
20220267384
2022-08-25

PROTEINS COMPRISING BINDING REGIONS, SHIGA TOXIN A SUBUNIT EFFECTOR REGIONS, AND CARBOXY-TERMINAL, ENDOPLASMIC RETICULUM LOCALIZATION SIGNAL MOTIFS

 #81
20220257653
2022-08-18

CHIMERIC ANTIGEN RECEPTORS CONTAINING GLYPICAN 2 BINDING DOMAINS

 #82
20220251212
2022-08-11

ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORS

 #83
20220202904
2022-06-30

COMBINED PHARMACEUTICAL COMPOSITION

 #84
20220193197
2022-06-23

SYNERGISTIC TUMOR TREATMENT WITH IL-2 AND INTEGRIN-BINDING-FC FUSION PROTEIN

 #85
20220169746
2022-06-02

ANTIBODIES TO NEOANTIGENS AND USES THEREOF

 #86
20220168395
2022-06-02

COMBINED PHARMACEUTICAL COMPOSITION

 #87
20220135635
2022-05-05

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #88
20220127354
2022-04-28

ANTIBODIES TARGETING CDH19 FOR MELANOMA

 #89
20220119470
2022-04-21

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #90
20220112253
2022-04-14

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #91
20220106396
2022-04-07

Anti Human Interleukin-1 Receptor Accessory Protein (IL1 RAP) Antibodies and Uses Thereof

 #92
20220089771
2022-03-24

Targeting intracellular target-binding determinants with intracellular antibodies

 #93
20220064296
2022-03-03

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #94
20220064241
2022-03-03

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #95
20220064240
2022-03-03

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #96
20220048964
2022-02-17

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #97
20220047620
2022-02-17

BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT

 #98
20210403562
2021-12-30

Bispecific antibody molecules binding to CD3 and EGFRvIII

 #99
20210401888
2021-12-30

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #100
20210393692
2021-12-23

COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER

 #101
20210388113
2021-12-16

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

 #102
20210388111
2021-12-16

Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same

 #103
20210371541
2021-12-02

CONJUGATED ANTIBOIDES AGAINST LY75 FOR THE TREATMENT OF CANCER

 #104
20210340253
2021-11-04

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

 #105
20210340203
2021-11-04

Peptides for use in immunotherapy against cancers

 #106
20210340202
2021-11-04

Peptides for use in immunotherapy against cancers

 #107
20210332132
2021-10-28

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

 #108
20210292411
2021-09-23

METHOD OF TREATING CANCER

 #109
20210284737
2021-09-16

ANTIBODY MOLECULES TO PD-L1 AND USES THEREOF

 #110
20210283169
2021-09-16

BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT

 #111
20210277081
2021-09-09

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #112
20210269548
2021-09-02

Antibody binding to chondroitin sulfate proteoglycan 5

 #113
20210261686
2021-08-26

ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF

 #114
20210253704
2021-08-19

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #115
20210253703
2021-08-19

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #116
20210252067
2021-08-19

METHODS AND COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR TARGETING CANCER CELLS

 #117
20210252061
2021-08-19

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #118
20210238303
2021-08-05

ANTI-TROP2 ANTIBODY-DRUG CONJUGATE

 #119
20210238284
2021-08-05

Methods for manipulating phagocytosis mediated by CD47

 #120
20210221895
2021-07-22

IL13Rα2 binding agents and use thereof

 #121
20210221863
2021-07-22

Interleukin-2 and use thereof

 #122
20210213102
2021-07-15

NOVEL INTERLEUKIN-2 AND USE THEREOF

 #123
20210188999
2021-06-24

ABCB5 LIGANDS AND SUBSTRATES

 #124
20210188998
2021-06-24

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCERS

 #125
20210179713
2021-06-17

ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USE THEREOF

 #126
20210171656
2021-06-10

Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies

 #127
20210139597
2021-05-13

Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

 #128
20210101979
2021-04-08

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #129
20210095043
2021-04-01

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

 #130
20210079113
2021-03-18

CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO

 #131
20210077528
2021-03-18

Modified cell with enhanced functionality and cellular therapy thereof

 #132
20210070882
2021-03-11

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #133
20210069250
2021-03-11

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #134
20210054021
2021-02-25

Stabilized immunoglobulin domains

 #135
20210000951
2021-01-07

COMBINATION THERAPIES

 #136
20200405878
2020-12-31

ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES

 #137
20200405855
2020-12-31

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS

 #138
20200399366
2020-12-24

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS

 #139
20200392246
2020-12-17

Antibodies to human B7x for treatment of metastatic cancer

 #140
20200385470
2020-12-10

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #141
20200385441
2020-12-10

IMMUNOTHERAPEUTIC COMPOSITION FOR THE TREATMENT OF CANCER

 #142
20200385440
2020-12-10

MODIFIED BISPECIFIC T CELL RECEPTORS

 #143
20200384022
2020-12-10

Methods and compositions for targeting developmental and oncogenic programs in H3K27M gliomas

 #144
20200377615
2020-12-03

SITE SPECIFIC HER2 ANTIBODY DRUG CONJUGATES

 #145
20200354472
2020-11-12

Antibodies targeting glioblastoma stem-like cells and methods of use thereof

 #146
20200339696
2020-10-29

Methods of producing an IL-1 RAP antibodies

 #147
20200325228
2020-10-15

COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER

 #148
20200325194
2020-10-15

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #149
20200291480
2020-09-17

Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer

 #150
20200291084
2020-09-17

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #151
20200277378
2020-09-03

COMBINATION THERAPIES

 #152
20200276307
2020-09-03

Anti-ErbB3 antibodies and uses thereof

 #153
20200276290
2020-09-03

Combination vaccine devices and methods of killing cancer cells

 #154
20200270347
2020-08-27

Bispecific antibody molecules binding to CD3 and TYRP-1

 #155
20200270321
2020-08-27

ANTIGEN BINDING MOLECULES COMPRISING A TRIMERIC TNF FAMILY LIGAND

 #156
20200262896
2020-08-20

Melanin antibodies and uses thereof

 #157
20200231673
2020-07-23

Bispecific T cell activating antigen binding molecules

 #158
20200216558
2020-07-09

Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof

 #159
20200200758
2020-06-25

CANCER MARKERS AND METHODS OF USE THEREOF

 #160
20200197518
2020-06-25

Combination therapy comprising nivolumab and ipilimumab

 #161
20200165335
2020-05-28

HUMANIZED ANTIBODIES TO LIV-1 AND USE OF SAME TO TREAT CANCER

 #162
20200157241
2020-05-21

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

 #163
20200155676
2020-05-21

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS

 #164
20200155602
2020-05-21

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #165
20200123221
2020-04-23

T cell receptors and immune therapy using the same against PRAME positive cancers

 #166
20200102359
2020-04-02

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #167
20200101160
2020-04-02

Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

 #168
20200095319
2020-03-26

CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS

 #169
20200078457
2020-03-12

Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

 #170
20200071419
2020-03-05

ANTIBODIES TO NON-FUNCTIONAL P2X7 RECEPTOR

 #171
20200071411
2020-03-05

Bispecific antibodies specific for OX40

 #172
20200071405
2020-03-05

ANTIBODY CONSTRUCTS FOR CDH19 AND CD3

 #173
20200062861
2020-02-27

Glycosynthase variants for glycoprotein engineering and methods of use

 #174
20200055947
2020-02-20

BI-SPECIFIC ACTIVATORS FOR TUMOR THERAPY

 #175
20200054761
2020-02-20

METHODS AND COMPOSITION FOR INHIBITING TUMOR GROWTH AND ENHANCING IMMUNE RESPONSES TO TUMORS

 #176
20200054678
2020-02-20

T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF

 #177
20200040100
2020-02-06

Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents

 #178
20200017584
2020-01-16

Modulation of stimulatory and non-stimulatory myeloid cells

 #179
20200010538
2020-01-09

Methods of treating skin cancer by administering a PD-1 inhibitor

 #180
20200000848
2020-01-02

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #181
20190388468
2019-12-26

Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor

 #182
20190375818
2019-12-12

Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms

 #183
20190352359
2019-11-21

Peptides for use in immunotherapy against cancers

 #184
20190343925
2019-11-14

Synergistic tumor treatment with an extended pharmacokinetic IL-2 and integrin-binding-Fc fusion protein

 #185
20190330356
2019-10-31

Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor

 #186
20190307801
2019-10-10

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #187
20190300616
2019-10-03

Conjugates of IL13Rα2 binding agents and use thereof in cancer treatment

 #188
20190270826
2019-09-05

ANTI-IL1RAP ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND IL1RAP AND CD3, AND USES THEREOF

 #189
20190270779
2019-09-05

Re-directed immunotherapy

 #190
20190256572
2019-08-22

T cell receptors and immune therapy using the same against prame positive cancers

 #191
20190248917
2019-08-15

Combination of ABCG2 inhibitors with sacituzumab govitecan (IMMU-132) overcomes resistance to SN-38 in Trop-2 expressing cancers

 #192
20190233515
2019-08-01

Methods for Manipulating Phagocytosis Mediated by CD47

 #193
20190227067
2019-07-25

METHOD AND KIT FOR DETERMINING PROGNOSIS, REMOTE RECURRENCE RISK AND INVASION OF GLIOMA, AND PHARMACEUTICAL COMPOSITION FOR TREATING GLIOMA

 #194
20190227052
2019-07-25

Method for screening antibody using patient-derived tumor spheroids

 #195
20190216908
2019-07-18

Adoptive t-cell therapy

 #196
20190202924
2019-07-04

Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof

 #197
20190194347
2019-06-27

ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)

 #198
20190194335
2019-06-27

Antibodies specific for epidermal growth factor receptor variant III and their uses

 #199
20190192571
2019-06-27

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #200
20190185574
2019-06-20

Antibody directed against the endothelin receptor beta sub-type

 #201
20190185554
2019-06-20

Targeting CLPTM1L for treatment and prevention of cancer

 #202
20190177435
2019-06-13

COMPOSITIONS AND METHODS FOR TREATMENT AND DETECTION OF CANCERS

 #203
20190177426
2019-06-13

Anti-fibulin-3 antibodies and uses thereof

 #204
20190177413
2019-06-13

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #205
20190177383
2019-06-13

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #206
20190169309
2019-06-06

REMOVAL OF CANCER CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING CANCER CELL TARGETED MHC CLASS 1 COMPROMISING MULTI-FUNCTION PROTEINS

 #207
20190169261
2019-06-06

T cell receptors and uses thereof

 #208
20190144559
2019-05-16

Anti-TROP2 antibody-drug conjugate

 #209
20190135939
2019-05-09

Anti-CSPG4 fusions with interferon for the treatment of malignancy

 #210
20190134216
2019-05-09

ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES

 #211
20190117693
2019-04-25

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #212
20190111081
2019-04-18

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #213
20190106507
2019-04-11

Antibody-drug conjugates containing anti-Globo H antibodies and uses thereof

 #214
20190106506
2019-04-11

CONJUGATED ANTIBODIES AGAINST LY75 FOR THE TREATMENT OF CANCER

 #215
20190092824
2019-03-28

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #216
20190062456
2019-02-28

Antibodies against CD73 and uses thereof

 #217
20190060351
2019-02-28

BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT

 #218
20190060350
2019-02-28

BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT

 #219
20190054145
2019-02-21

Methods of treating cancer cells expressing tumor-associated integrins

 #220
20190040143
2019-02-07

Binding molecules specific for HER3 and uses thereof

 #221
20190030075
2019-01-31

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #222
20190023783
2019-01-24

METHOD OF TREATING CANCER

 #223
20190016805
2019-01-17

Antibody constructs for CDH19 and CD3

 #224
20190002565
2019-01-03

Bispecific T cell activating antigen binding molecules

 #225
20190002564
2019-01-03

Bispecific T cell activating antigen binding molecules

 #226
20180346572
2018-12-06

Anti-PD-L1 combinations for treating tumors

 #227
20180346538
2018-12-06

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #228
20180312603
2018-11-01

PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF CANCERS

 #229
20180291114
2018-10-11

RECOMBINANT BI-SPECIFIC POLYPEPTIDE FOR COORDINATELY ACTIVATING TUMOR-REACTIVE T-CELLS AND NEUTRALIZING IMMUNE SUPPRESSION

 #230
20180273643
2018-09-27

BISPECIFIC T CELL ACTIVATING ANTIGEN BINDING MOLECULES

 #231
20180256680
2018-09-13

H3T3A mutant protein efficiently reduces H3T3P and causes increased cell death of rapidly dividing cells

 #232
20180251566
2018-09-06

Antibody drug conjugates (ADC) that bind to 158P1D7 proteins

 #233
20180251506
2018-09-06

Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

 #234
20180251503
2018-09-06

MULTIMERIZATION TECHNOLOGIES

 #235
20180237538
2018-08-23

Recombinant human IgM-antibody effective against cancer cells

 #236
20180230205
2018-08-16

Antibodies to endoplasmin and their use

 #237
20180222981
2018-08-09

Bispecific T cell activating antigen binding molecules

 #238
20180222980
2018-08-09

Bispecific T cell activating antigen binding molecules

 #239
20180222973
2018-08-09

Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer

 #240
20180208673
2018-07-26

USES OF MONOCLONAL ANTIBODY 8H9

 #241
20180208657
2018-07-26

RECOMBINANT ANTIBODY MOLECULE AND ITS USE FOR TARGET CELL RESTRICTED T CELL ACTIVATION

 #242
20180208654
2018-07-26

Antibodies targeting CDH19 for melanoma

 #243
20180186882
2018-07-05

Antibody molecules to PD-L1 and methods of treating cancer

 #244
20180179283
2018-06-28

T CELL RECEPTOR LIKE ANTIBODIES HAVING FINE SPECIFICITY

 #245
20180171024
2018-06-21

Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same

 #246
20180148508
2018-05-31

Masking chimeric antigen receptor T cells for tumor-specific activation

 #247
20180148503
2018-05-31

T cell receptor-like antibodies specific for a PRAME peptide

 #248
20180142033
2018-05-24

Cancer therapy using CLDN6 target-directed antibodies in vivo

 #249
20180142021
2018-05-24

Bispecific antibody constructs for CDH3 and CD3

 #250
20180134796
2018-05-17

IL13Rα2 binding agents and use thereof in cancer treatment

 #251
20180128817
2018-05-10

Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy

 #252
20180125999
2018-05-10

Anti-EGFR antibodies and antibody drug conjugates

 #253
20180112006
2018-04-26

AGENTS, SYSTEMS AND METHODS FOR TREATING CANCER

 #254
20180110860
2018-04-26

Immune conjugate having dendron conjugated to antibody and use thereof

 #255
20180094074
2018-04-05

IgE anti-HMW-MAA antibody

 #256
20180094073
2018-04-05

Anti-TROP2 antibody-drug conjugate

 #257
20180086849
2018-03-29

Bispecific T cell activating antigen binding molecules

 #258
20180079810
2018-03-22

Humanized Antibodies To LIV-1 And Use Of Same To Treat Cancer

 #259
20180074065
2018-03-15

Systems and methods for anti-SOX10 antibodies

 #260
20180072811
2018-03-15

Anti-CSPG4 reagents and methods of treating cancer

 #261
20180066032
2018-03-08

NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS

 #262
20180057608
2018-03-01

BISPECIFIC ANTIBODY MOLECULE

 #263
20180057589
2018-03-01

ANTI-NOTCH2 NRR ANTIBODIES

 #264
20180055883
2018-03-01

Peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

 #265
20180036406
2018-02-08

Anti-ErbB3 antibodies and uses thereof

 #266
20180022818
2018-01-25

METHODS AND PRODUCTS FOR PREVENTING AND/OR TREATING METASTATIC CANCER

 #267
20180021431
2018-01-25

Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors

 #268
20180011095
2018-01-11

Monoclonal antibody for the diagnosis, treatment and/or prevention of brain tumors and brain lesions

 #269
20180002430
2018-01-04

Methods of treating cancer using anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies

 #270
20170369588
2017-12-28

PRO-APOPTOTIC ANTI-NG2/CSPG4 ANTIBODIES AND THEIR USES FOR DISEASE THERAPY

 #271
20170368172
2017-12-28

Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

 #272
20170342151
2017-11-30

Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof

 #273
20170333384
2017-11-23

METHODS OF TREATING MELANOMA

 #274
20170327592
2017-11-16

Polypeptide immunogen for generating an antibody to non-functional P2X7 receptor

 #275
20170327590
2017-11-16

Methods of treating skin cancer by administering a PD-1 inhibitor

 #276
20170320945
2017-11-09

Methods for manipulating phagocytosis mediated by CD47

 #277
20170313781
2017-11-02

Efficacy of anti-trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors

 #278
20170307621
2017-10-26

Platform for the identification of tumor-associated cancer/testes antigens

 #279
20170298142
2017-10-19

Antibodies to GRP78

 #280
20170291946
2017-10-12

Modulation of stimulatory and non-stimulatory myeloid cells

 #281
20170275700
2017-09-28

METHODS AND MATERIALS FOR IDENTIFYING METASTATIC MALIGNANT SKIN LESIONS AND TREATING SKIN CANCER

 #282
20170274085
2017-09-28

Drug delivery of temozolomide for systemic based treatment of cancer

 #283
20170274074
2017-09-28

Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer

 #284
20170274073
2017-09-28

METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS

 #285
20170258905
2017-09-14

Methods and compositions for enhancing the potency of superantigen mediated cancer immunotherapy

 #286
20170258835
2017-09-14

METHODS AND COMPOSITIONS FOR MODIFIED T CELLS

 #287
20170253665
2017-09-07

Antibodies against CD73

 #288
20170247417
2017-08-31

T-cell redirecting bispecific antibodies for treatment of disease

 #289
20170240645
2017-08-24

Anti-PMEL17 antibodies and immunoconjugates

 #290
20170240638
2017-08-24

Enhancing the therapeutic activity of immune checkpoint inhibitor

 #291
20170224837
2017-08-10

COMBINATION OF ABCG2 INHIBITORS WITH SACITUZUMAB GOVITECAN (IMMU-132) OVERCOMES RESISTANCE TO SN-38 IN TROP-2 EXPRESSING CANCERS

 #292
20170218086
2017-08-03

Methods and materials for treating cancer

 #293
20170218078
2017-08-03

Bispecific T cell engaging antibody constructs

 #294
20170216403
2017-08-03

SYNERGISTIC TUMOR TREATMENT WITH IL-2, A THERAPEUTIC ANTIBODY, AND AN IMMUNE CHECKPOINT BLOCKER

 #295
20170216402
2017-08-03

Synergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein

 #296
20170210812
2017-07-27

Antibodies specific for epidermal growth factor receptor variant III and their uses

 #297
20170209574
2017-07-27

COMBINATION THERAPIES

 #298
20170204175
2017-07-20

ANTI-NOTCH2 NRR ANTIBODIES

 #299
20170198043
2017-07-13

BISPECIFIC ANTIGEN BINDING MOLECULES

 #300
20170190788
2017-07-06

USES OF ANTI-HER3 ANTIBODIES FOR TREATING CANCER